Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia

Am Health Drug Benefits. 2016 Mar;9(Spec Feature):136-9.

Loretta Fala

PMID: 27668060

Products

Cat. No.

Product Name

Description

Target

Research Area
HY-P9930

Evolocumab

98.40%, PCSK9 Inhibitor

NF-κB; Ser/Thr Protease; Toll-like Receptor (TLR)

Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease; Cancer

MedChemExpress Magic Cece

MedChemExpress: Contact Us; About Us; Headquarters; Distributors; Statement on False Report; Careers

Customer Support: Technical Support; Service; Ordering Information; Easy Return; Shipping Rates & Policies; Intellectual Property Promise

Resources: Free Sample; Resources; Molarity Calculator; Dilution Calculator; Terms & Conditions; Reconstitution Calculator; Specific Activity Calculator

Subscribe to our E-newsletter

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.

Copyright © 2013-2024 MedChemExpress. All Rights Reserved.: Site Map Privacy Policy

Join with us